1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall

 
• By Sue Sutter

FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.

The silver lining in GlaxoSmithKline PLC’s unsuccessful initial bid for a pediatric asthma claim for Breo Ellipta (fluticasone furoate/vilanterol) is the ability of its own respiratory franchise standard-bearer Advair (fluticasone/salmeterol) to fill the gap.

GSK will continue to promote Advair’s pediatric asthma indication, with its recently reorganized respiratory sales force, it confirmed during a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

 
• By Sarah Karlin-Smith and Derrick Gingery

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.

PCMA, CVS, Cigna File Lawsuits Over ‘Dangerous’ Arkansas PBM Law

 
• By Tim Casey

The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.